Business Segments · Acquired in-process research and development expenses
Business Segments — Acquired in-process research and development expenses
Pfizer Business Segments — Acquired in-process research and development expenses increased by 1422.2% to $137.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toAcquired IPR&D Expense
How to read this metric
High spending indicates an aggressive inorganic growth strategy to fill pipeline gaps.
Detailed definition
Costs associated with the acquisition of early-stage research projects or pipeline assets from third parties. These expe...
Peer comparison
Common in the pharma industry as companies frequently buy smaller biotech firms to replenish their pipelines.
Metric ID:
pfe_segment_biopharma_acquired_in_process_research_and_development_expensesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $9.00M | $137.00M |
| QoQ Change | — | >999% |
| YoY Change | — | >999% |
Range$9.00M – $137.00M
Avg YoY Growth>999%
Median YoY Growth>999%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — acquired in-process research and development expenses?
- Pfizer (PFE) reported business segments — acquired in-process research and development expenses of $137.00M in Q1 2026.
- What does business segments — acquired in-process research and development expenses mean?
- Costs incurred to acquire research and development projects from other companies.